Please login to the form below

Not currently logged in
Email:
Password:

Protelos

This page shows the latest Protelos news and features for those working in and with pharma, biotech and healthcare.

CHMP turns down Avastin for brain cancer

CHMP turns down Avastin for brain cancer

Both drugs were originally rejected earlier this year. It also reported that Servier had elected to withdraw its application to extend the indications of its osteoporosis therapy Protelos/Osser (strontium ranelate)

Latest news

  • EMA recommends heart risk restriction for Servier's Protelos EMA recommends heart risk restriction for Servier's Protelos

    EMA recommends heart risk restriction for Servier's Protelos. Use of osteoporosis drug likely to be further tightened up. ... That review brought restrictions that included a prohibition on the use of Protelos' in immobilised patients or patients with a

  • EMA restricts use of Servier’s Protelos and Osseor

    EMA restricts use of Servier’ s Protelos and Osseor. Osteoporosis drugs not to be used in patients with history of blood clots. ... Elderly patients were also shown to be more at risk of contracting VTE after use of Protelos and Osseor compared with

  • Process for NICE guidance re-evaluation

    Servier Laboratories, the licence holder of Protelos (strontium ranelate), which instigated the review, remains satisfied with Mr Holman's judgement that NICE acted with procedural unfairness, and therefore unlawfully, by not

  • High Court rules against NICE in osteoporosis case

    High Court rules against NICE in osteoporosis case. The High Court has ruled that NICE must look again at its decision not to fund the use of osteoporosis drug Protelos on ... The High Court has ruled that the National Institute for Health and Clinical

  • R&D News in brief

    Protelos shines in study. Servier's osteoporosis treatment, Protelos, is effective in reducing nonvertebral and vertebral fractures over five years, according to two new studies presented at the Sixth European Congress ... One trial of 1649

More from news
Approximately 1 fully matching, plus 9 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Anthill Agency

Digital communications agency empowering clients through their digital transformation journey. Whether through training, delivering solutions or devising digital strategies, we...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics